Bristol-Myers Squibb has completed its previously announced divestment of its oral solid, biologics, and sterile-product manufacturing and packaging facility in Anagni, Italy, to Catalent.

The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. The 28,000 square-meter facility has capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, and primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products.

The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline.

As part of the acquisition, Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site. Catalent has also announced that it plans to make further investments in the site’s growth.

Source: Bristol-Myers Squibb and Catalent